{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:52:53Z","timestamp":1792896773296,"version":"4.5.0"},"reference-count":141,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Tissue-resident memory T (T<jats:sub>RM<\/jats:sub>) cells have emerged as key players in the immune control of melanoma. These specialized cells are identified by expression of tissue retention markers such as CD69, CD103 and CD49a with downregulation of egress molecules such as Sphingosine-1-Phosphate Receptor-1 (S1PR1) and the lymphoid homing receptor, CD62L. T<jats:sub>RM<\/jats:sub> have been shown to be integral in controlling infections such as herpes simplex virus (HSV), lymphocytic choriomeningitis virus (LCMV) and influenza. More recently, robust pre-clinical models have also demonstrated T<jats:sub>RM<\/jats:sub> are able to maintain melanoma in a dormant state without progression to macroscopic disease reminiscent of their ability to control viral infections. The discovery of the role these cells play in anti-melanoma immunity has coincided with the advent of immune checkpoint inhibitor (ICI) therapy which has revolutionized the treatment of cancers. ICIs that target programmed death protein-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) have led to substantial improvements in outcomes for patients with metastatic melanoma and have been rapidly employed to reduce recurrences in the resected stage III setting. While ICIs mediate anti-tumor activity <jats:italic>via<\/jats:italic> CD8<jats:sup>+<\/jats:sup> T cells, the specific subsets that facilitate this response is unclear. T<jats:sub>RM<\/jats:sub> invariably exhibit high expression of immune checkpoints such as PD-1, CTLA-4 and lymphocyte activating gene-3 (LAG-3) which strongly implicates this CD8<jats:sup>+<\/jats:sup> T cell subset as a crucial mediator of ICI activity. In this review, we present pre-clinical and translational studies that highlight the critical role of T<jats:sub>RM<\/jats:sub> in both immune control of primary melanoma and as a key CD8<jats:sup>+<\/jats:sup> T cell subset that mediates anti-tumor activity of ICIs for the treatment of melanoma.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1048758","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T05:59:35Z","timestamp":1668578375000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management"],"prefix":"10.3389","volume":"13","author":[{"given":"Kai R.","family":"Plunkett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse D.","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrisha-Jade","family":"Inderjeeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Waithman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K. H.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the international neoadjuvant melanoma consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2257","article-title":"CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment","volume":"24","author":"Edwards","year":"2018","journal-title":"Clin Cancer Res: an Off J Am Assoc Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.88955","article-title":"Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells","volume":"1","author":"Boddupalli","year":"2016","journal-title":"JCI Insight"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0812-9","article-title":"Tissue-resident memory CD8(+) T cells promote melanoma-immune equilibrium in skin","volume":"565","author":"Park","year":"2019","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1718","article-title":"Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus","volume":"10","author":"Gebhardt","year":"2009","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"279ra39","DOI":"10.1126\/scitranslmed.3010302","article-title":"Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells","volume":"7","author":"Watanabe","year":"2015","journal-title":"Sci Trans Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002231","article-title":"Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade","volume":"9","author":"Banchereau","year":"2021","journal-title":"J immunotherapy cancer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/imr.12650","article-title":"Tissue-resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance","volume":"283","author":"Gebhardt","year":"2018","journal-title":"Immunol Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2013.26","article-title":"Skin-resident memory T cells keep herpes simplex virus at bay","volume":"91","author":"Gebhardt","year":"2013","journal-title":"Immunol Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00573","article-title":"Very late antigen-1 marks functional tumor-resident CD8 T cells and correlates with survival of melanoma patients","volume":"7","author":"Murray","year":"2016","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.cell.2020.05.039","article-title":"Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma","volume":"182","author":"Ji","year":"2020","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001807","article-title":"CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma","volume":"9","author":"Lai","year":"2021","journal-title":"J Immunother Canc"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1877","article-title":"Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer","volume":"20","author":"Webb","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.02.026","article-title":"CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma","volume":"60","author":"Workel","year":"2016","journal-title":"Eur J Canc"},{"key":"B25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5152\/balkanmedj.2021.21122","article-title":"Prognostic value of tissue-resident memory T cells and tumor microenvironmental features in resected pancreatic adenocarcinoma","volume":"39","author":"Ba\u015fo\u011flu","year":"2022","journal-title":"Balkan Med J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-Expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402711","article-title":"CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients","volume":"194","author":"Djenidi","year":"2015","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.02.010","article-title":"Understanding subset diversity in T cell memory","volume":"48","author":"Jameson","year":"2018","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343751","article-title":"The who\u2019s who of T-cell differentiation: human memory T-cell subsets","volume":"43","author":"Mahnke","year":"2013","journal-title":"Eur J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.06.002","article-title":"Tissue-resident memory T cells in cancer immunosurveillance","volume":"40","author":"Park","year":"2019","journal-title":"Trends Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1516485113","article-title":"T Cell-intrinsic S1PR1 regulates endogenous effector T-cell egress dynamics from lymph nodes during infection","volume":"113","author":"Benechet","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2744","article-title":"The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin","volume":"14","author":"Mackay","year":"2013","journal-title":"Nat Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn1889","article-title":"Central memory T cells are the most effective precursors of resident memory T cells in human skin","volume":"7","author":"Matos","year":"2022","journal-title":"Sci Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1202288109","article-title":"Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation","volume":"109","author":"Mackay","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.11.008","article-title":"T-Box transcription factors combine with the cytokines TGF-\u03b2 and IL-15 to control tissue-resident memory T cell fate","volume":"43","author":"Mackay Laura","year":"2015","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402256","article-title":"Cutting edge: CD69 interference with sphingosine-1-Phosphate receptor function regulates peripheral T cell retention","volume":"194","author":"Mackay","year":"2015","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01004-1","article-title":"Discrete tissue microenvironments instruct diversity in resident memory T cell function and plasticity","volume":"22","author":"Christo","year":"2021","journal-title":"Nat Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3108","article-title":"Proinflammatory microenvironments within the intestine regulate the differentiation of tissue-resident CD8+ T cells responding to infection","volume":"16","author":"Bergsbaken","year":"2015","journal-title":"Nat Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400003","article-title":"Cutting edge: Resident memory CD8 T cells occupy frontline niches in secondary lymphoid organs","volume":"192","author":"Schenkel","year":"2014","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01229-8","article-title":"Tissue-resident memory CD8+ T cells possess unique transcriptional, epigenetic and functional adaptations to different tissue environments","volume":"23","author":"Crowl","year":"2022","journal-title":"Nat Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1915681117","article-title":"TRM integrins CD103 and CD49a differentially support adherence and motility after resolution of influenza virus infection","volume":"117","author":"Reilly","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"108085","DOI":"10.1016\/j.celrep.2020.108085","article-title":"CD49a regulates cutaneous resident memory CD8(+) T cell persistence and response","volume":"32","author":"Bromley","year":"2020","journal-title":"Cell Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1308209110","article-title":"Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors","volume":"110","author":"Beavis","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.3390\/ijms19123837","article-title":"Targeting adenosine receptor signaling in cancer immunotherapy","volume":"19","author":"Sek","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/ph13090237","article-title":"Tumor immunotherapy using A(2A) adenosine receptor antagonists","volume":"13","author":"Zhang","year":"2020","journal-title":"Pharm (Basel)."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0211","article-title":"Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses","volume":"3","author":"Beavis","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.979993","article-title":"Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome","volume":"13","author":"Attrill","year":"2022","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004771","article-title":"Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy","volume":"10","author":"Attrill","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad2035","article-title":"Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes","volume":"352","author":"Mackay","year":"2016","journal-title":"Science"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149665","article-title":"Hobit and blimp-1 regulate TRM abundance after LCMV infection by suppressing tissue exit pathways of TRMprecursors","volume":"52","author":"Parga-Vidal","year":"","journal-title":"Eur J Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01273-4","article-title":"Runx3 drives a CD8+ T cell tissue residency program that is absent in CD4+ T cells","volume":"23","author":"Fonseca","year":"2022","journal-title":"Nat Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3589","article-title":"Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells","volume":"17","author":"Hombrink","year":"2016","journal-title":"Nat Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201556","article-title":"Differential localization of T-bet and eomes in CD8 T cell memory populations","volume":"190","author":"McLane","year":"2013","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138970","article-title":"Hypoxia acts as an environmental cue for the human tissue-resident memory T cell differentiation program","volume":"6","author":"Hasan","year":"2021","journal-title":"JCI Insight"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85329","article-title":"ABC Transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells","volume":"126","author":"Boddupalli","year":"2016","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.03.017","article-title":"Transcriptional programming of tissue-resident memory CD8(+) T cells","volume":"51","author":"Milner","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1322292111","article-title":"Persistence of skin-resident memory T cells within an epidermal niche","volume":"111","author":"Zaid","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B66","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ccell.2022.04.005","article-title":"An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes","volume":"40","author":"Jaiswal","year":"2022","journal-title":"Cancer Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00619-11","article-title":"Targeting OX40 promotes lung-resident memory CD8 T cell populations that protect against respiratory poxvirus infection","volume":"85","author":"Salek-Ardakani","year":"2011","journal-title":"J Virol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0702","article-title":"Fatty acid oxidation controls CD8(+) tissue-resident memory T-cell survival in gastric adenocarcinoma","volume":"8","author":"Lin","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.162","article-title":"T-Cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Disease"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01313.x","article-title":"PD-1\/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection","volume":"17","author":"Watanabe","year":"2010","journal-title":"J Viral Hepatitis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1442163","article-title":"Vaccination-induced skin-resident memory CD8(+) T cells mediate strong protection against cutaneous melanoma","volume":"7","author":"Galvez-Cancino","year":"2018","journal-title":"Oncoimmunology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4011","article-title":"Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naive melanoma patients: Implications for clinical trials","volume":"25","author":"Edwards","year":"2019","journal-title":"Clin Cancer Res: an Off J Am Assoc Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"B77","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","article-title":"Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors","volume":"1","author":"Linsley","year":"1994","journal-title":"Immunity"},{"key":"B78","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.185.3.393","article-title":"CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics","volume":"185","author":"van der Merwe","year":"1997","journal-title":"J Exp Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2017.07.014","article-title":"Lessons from CTLA-4 deficiency and checkpoint inhibition","volume":"49","author":"Lo","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Canc"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01176-4","article-title":"LAG3 associates with TCR\u2013CD3 complexes and suppresses signaling by driving co-receptor\u2013lck dissociation","volume":"23","author":"Guy","year":"2022","journal-title":"Nat Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0143","article-title":"Reflections on the histopathology of tumor-infiltrating lymphocytes in melanoma and the host immune response","volume":"3","author":"Mihm","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.24.1893","article-title":"Model predicting survival in stage I melanoma based on tumor progression","volume":"81","author":"Clark","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","article-title":"Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma","volume":"77","author":"Clemente","year":"1996","journal-title":"Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma","volume":"30","author":"Azimi","year":"2012","journal-title":"J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1593806","DOI":"10.1080\/2162402X.2019.1593806","article-title":"Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis","volume":"8","author":"Fu","year":"2019","journal-title":"Oncoimmunology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.15698\/cst2019.05.187","article-title":"Tissue-resident memory T cells orchestrate tumour-immune equilibrium","volume":"3","author":"Park","year":"2019","journal-title":"Cell Stress."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200302063480620","article-title":"Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery","volume":"348","author":"MacKie","year":"2003","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12989","article-title":"Genomic analysis of melanoma evolution following a 30-year disease-free interval","volume":"44","author":"Miller","year":"2017","journal-title":"J Cutaneous Pathol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21821","article-title":"Ultra-late recurrence of malignant melanoma after 40 years of quiescent disease","volume":"103","author":"Saleh","year":"2011","journal-title":"J Surg Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03330.x","article-title":"Ultra-late recurrence of malignant melanoma after a disease-free interval of 41 years","volume":"35","author":"Terhorst","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9919","article-title":"Macrophage markers in serum and tumor have prognostic impact in American joint committee on cancer stage I\/II melanoma","volume":"27","author":"Jensen","year":"2009","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21283","article-title":"The predictive value of CD8, CD4, CD68, and human leukocyte antigen-d-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase","volume":"104","author":"Piras","year":"2005","journal-title":"Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002995","article-title":"Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the innate PD-1 resistance signature (IPRES)","volume":"9","author":"Lau","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/Anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3","volume":"138","author":"Boniface","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.032","article-title":"Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo","volume":"139","author":"Richmond","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00180-1","article-title":"Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy","volume":"2","author":"Han","year":"2021","journal-title":"Nat Canc"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12077","article-title":"CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCR\u03b1\u03b2+ CD8\u03b1\u03b2+ T cells that can be targeted for cancer immunotherapy","volume":"7","author":"Komdeur","year":"2016","journal-title":"Oncotarget"},{"key":"B112","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1038\/s41467-019-12319-x","article-title":"Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells","volume":"10","author":"Menares","year":"2019","journal-title":"Nat Commun"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9505","article-title":"Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047","volume":"40","author":"Tawbi","year":"2022","journal-title":"J Clin Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","article-title":"PD-1 blockade expands intratumoral memory T cells","volume":"4","author":"Ribas","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-c and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","author":"Eggermont","year":"2022","journal-title":"NEJM Evidence"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00533","article-title":"Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-d or stage IV melanoma (CheckMate 915)","author":"Weber","year":"2022","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA9500","article-title":"Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study","volume":"40","author":"Long","year":"2022","journal-title":"J Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2015.12.008","article-title":"The molecular profile of metastatic melanoma in Australia","volume":"48","author":"Lyle","year":"2016","journal-title":"Pathology"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res: an Off J Am Assoc Cancer Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin Cancer Res: An Off J Am Assoc Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0030","article-title":"BRAFV600E Co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma","volume":"3","author":"Bradley","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246342","article-title":"Enhancing adoptive cell transfer with combination BRAF-MEK and CDK4\/6 inhibitors in melanoma","volume":"13","author":"Lau","year":"2021","journal-title":"Cancers"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J Exp Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9503","article-title":"NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy","volume":"40","author":"Long","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1048758\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T05:59:40Z","timestamp":1668578380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1048758\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":141,"alternative-id":["10.3389\/fimmu.2022.1048758"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1048758","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"article-number":"1048758"}}